Alzenau, Germany

Friedrich Wissmann

This inventor holds 2 USPTO granted patents and 1 EPO patent. Top assignee: W.c. Heraeus Gmbh. Active years: 2007-2010.


% Patents Active = 50.0


Average Co-Inventor Count = 3.4

ph-index = 1

Forward Citations = 6(Granted Patents)


Company Filing History:


Years Active: 2007-2010

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Friedrich Wissmann: Innovator in Pharmaceutical Chemistry

Introduction

Friedrich Wissmann is a notable inventor based in Alzenau, Germany. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of methods for preparing complex compounds. With a total of 2 patents to his name, Wissmann's work has had a meaningful impact on drug manufacturing processes.

Latest Patents

Wissmann's latest patents include innovative methods for preparing Irinotecan, a crucial drug used in cancer treatment. His patents detail processes for manufacturing 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxy-camptothecin. Additionally, he has developed a process for the preparation of 1,2-diaminocyclohexane-platinum(II) complexes, which involves the preparation of diaminocyclohexane-platinum(II)-dicarboxylates and the removal of the resulting AgX precipitate.

Career Highlights

Wissmann is currently employed at W.C. Heraeus GmbH, a company known for its advancements in materials and technology. His work at the company has allowed him to focus on innovative solutions in the pharmaceutical sector.

Collaborations

Throughout his career, Wissmann has collaborated with talented professionals, including Holger Rauter and Andreas Pepels. These collaborations have further enriched his research and development efforts.

Conclusion

Friedrich Wissmann stands out as an influential inventor in the pharmaceutical industry. His innovative patents and collaborative efforts continue to drive advancements in drug manufacturing processes.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…